CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01422486
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:35.969862+00:00
Published At: 2013-11-25T00:00:00+00:00
Record Updated At: 2013-11-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Myelodysplastic Syndrome (MDS)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-11-25"
protocolSection.identificationModule.nctId: "NCT01422486"
protocolSection.identificationModule.officialTitle: "Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra\u00ae) in Patients With Lenalidomide (Revlimid\u00ae) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.